Success Metrics

Active Trials

3(60%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Recruiting2

Not yet recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

recruiting240%

not_yet_recruiting240%

active_not_recruiting120%

Recent Activity

3 active trials

Showing 5 of 5

not_yet_recruitingphase_2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

NCT07527806

recruitingphase_1

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

NCT07145255

recruitingphase_2

ctDNA-guided Treatment Decision-making

NCT07394218

not_yet_recruiting

HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

NCT06798246

active_not_recruiting

The Rechallenge of ADCs in MBC Patients

NCT05571618

Clinical Trials (5)

Showing 5 of 5 trials

NCT07527806Phase 2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Not Yet Recruiting

NCT07145255Phase 1

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Recruiting

NCT07394218Phase 2